MTSR trades 21.3% above Wall Street's consensus target of $55.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes MTSR achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 30, 2026, Metsera, Inc. (MTSR) has a Wall Street consensus price target of $55.50, based on estimates from 4 covering analysts. With the stock currently trading at $70.50, this represents a potential downside of -21.3%. The company has a market capitalization of $7.43B.
Analyst price targets range from a low of $54.00 to a high of $57.00, representing a 5% spread in expectations. The median target of $55.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, MTSR trades at a trailing P/E of -34.7x. Analysts expect EPS to grow -14.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
VKTXViking Therapeutics, Inc. | $4.6B | $39.54 | $93.60 | +136.7% | Buy | — | 24 |
TERNTerns Pharmaceuticals, Inc. | $4.8B | $52.95 | $55.50 | +4.8% | Buy | — | 16 |
GPCRStructure Therapeutics Inc. | $3.0B | $51.69 | $111.60 | +115.9% | Buy | — | 14 |
PEPGPepGen Inc. | $123M | $1.78 | $5.50 | +209.0% | Buy | — | 6 |
NVONovo Nordisk A/S | $214.8B | $48.34 | $45.00 | -6.9% | Buy | 2.2x | 39 |
LLYEli Lilly and Company | $1.2T | $1229.93 | $1269.94 | +3.3% | Buy | 33.6x | 45 |
AMGNAmgen Inc. | $194.6B | $360.55 | $349.33 | -3.1% | Buy | 16.1x | 38 |
RYTMRhythm Pharmaceuticals, Inc. | $7.5B | $110.04 | $139.57 | +26.8% | Buy | — | 20 |
CGONCG Oncology, Inc. Common stock | $6.5B | $73.73 | $82.57 | +12.0% | Buy | — | 10 |
CVSCVS Health Corporation | $132.2B | $103.58 | $103.64 | +0.1% | Buy | 14.0x | 41 |
Quick answers to the most common questions about buying MTSR stock.
MTSR's consensus price target is $55.5, -21.3% below the current price of $70.5. The 4 analysts tracking MTSR see downside risk at present valuations.
MTSR has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $55.5 implies -21.3% downside from current levels.
MTSR's current price is $70.5 with a consensus target of $55.5 (-21.3% implied move). Analyst estimates suggest the stock is overvalued at current levels.
The most bullish Wall Street analyst has a price target of $57 for MTSR, while the most conservative target is $54. The consensus of $55.5 represents the median expectation. These targets typically reflect 12-month expectations.
MTSR is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month MTSR stock forecast based on 4 Wall Street analysts shows a consensus price target of $55.5, with estimates ranging from $54 (bear case) to $57 (bull case). The median consensus rating is "Buy".
Analysts are cautious on MTSR, with 0 Sell ratings and a price target of $55.5 (-21.3% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
MTSR analyst price targets range from $54 to $57, a 5% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $55.5 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.